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Abstract Disclosures
Background:
There is limited, often con icting evidence about AE timing, severity or associations with outcomes with
the use of cytotoxic agents in cancer treatment. We investigated the impact on overall survival (OS)
and progression-free survival (PFS) of selected common AEs (neutropenia, diarrhea, nausea, vomiting,
neuropathy) occurring in patients receiving  rst line oxaliplatin (Oxa)- and/or irinotecan(Iri)-based
regimens for mCRC.
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Methods:
The CTCAE grading scores of at least one AE of interest were available on 9812 pts treated with
chemotherapy alone (median age 63; 62.4% male, 50.1% ECOG PS 0) from 17 1 -line randomized
trials. Patients who also received biologics were excluded in the primary analyses. AEs occurring during
the  rst 6 weeks of treatment and entire treatment were analyzed by strati ed multivariable Cox
models in relationship to OS/PFS. 55.7% pts received Oxa- regimens, 35.7% Iri-regimens, and 8.6%
combined Oxa- and Iri-regimens.
Results:
Within the  rst 6 weeks of treatment, G3+ neutropenia (HR = 1.3, 95% CI, 1.06-1.59, p  0.01),
diarrhea (HR = 1.48, 95% CI, 1.23-1.79, p < .0001), nausea (HR = 1.53, 95% CI, 1.17-1.99, p
0.002) and vomiting (HR = 1.56, 95% CI, 1.18-2.07, p  0.002) were associated with signi cantly worse
OS for Iri-regimens, but only G3+ nausea predicted for worse OS for Oxa- regimens (HR = 1.61, 95%
CI, 1.18-2.21, p  0.003). For AEs experienced at any time, G3+ neutropenia and neuropathy were
signi cantly associated with longer PFS and OS for Oxa-regimens, while G3+ vomiting and nausea were
associated with worse OS for both Oxa- and Iri-based regimens. Sensitivity analysis showed largely
concordant results by including pts who also received biologics.
Conclusions:
The association between more severe selected AEs and outcome varies between AEs and is in uenced
by timing of the occurrence. More severe selected AEs occurring early in treatment are associated with
worse outcomes. In contrast, for AEs occurring at any time, G3+ neutropenia and neuropathy
predicted for longer PFS and/or OS in Oxa-treated pts.
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